Article

BMI Matters: Predicting Cardiovascular Event Risk

Author(s):

While various epidemiological studies have shown obesity to be linked with inflammation and with increased cardiovascular risk, the inflammatory marker C-reactive protein (CRP) takes it a step further, strongly predicting the incidence of cardiovascular events.

While various epidemiological studies have shown obesity to be linked with inflammation and with increased cardiovascular risk, the inflammatory marker C-reactive protein (CRP) takes it a step further, strongly predicting the incidence of cardiovascular events.

Whether CRP is equally predictive of cardiovascular event risk in obese patients and in non-obese subjects is not known and will be addressed in a presentation by Christoph H. Saely, MD, VIVIT Institute, Academic Teaching Hospital, Feldkirch, Austria at the American College of Cardiology (ACC) 64th Annual Scientific Meeting.

During a follow-up 10-year period, the researchers recorded cardiovascular events in a large population of 1,731 patients undergoing coronary angiography — evaluating the established or suspected stable coronary artery disease (CAD).

CRP was reported significantly higher in non-obese subjects (n=1,367) than obese individuals (n=364; 0.6±1.5 vs. 0.5±0.8 mg/dl; p<0.001). Meanwhile, approximately a quarter of the patients were reported to have suffered vascular events.

While CRP appeared to be a strong, independent predictor of vascular events in non-obese subjects, it did not show similar results in the obese group. However, an interaction term of BMI x CRP was found to be significant, demonstrating that the mass index weight considerably modified the power of CRP to predict vascular events.

“From the results of this large 10-year prospective cohort study we conclude that obesity significantly modulates the power of CRP to predict cardiovascular event risk among angiographied coronary patients,” wrote the authors.

Related Videos
Confirming Tapinarof’s Efficacy and Safety Across Atopic Dermatitis Severities, with Justin Greiwe, MD
Investigating Briquilimab’s Efficacy and Safety for CSU, with Thomas Casale, MD
What to Look Forward to at the American Academy of Dermatology Annual Meeting 2025
Improving Care for ISM With Better Diagnosis, Disease Characterization, with Thanai Pongdee, MD
John Barbieri, MD, MBA | Credit: Brigham and Women's Hospital
Robert Wood, MD I Credit: Johns Hopkins Medicine
Achieving Chronic Spontaneous and Inducible Urticaria Control With Barzolvolimab, with Martin Metz, MD
Scott Commins, MD, PhD I Credit: UNC School of Medicine
Optimizing ISM Treatment Beyond Approval, with Vito Sabato, MBBS
Updated Treatment Strategies for Pediatric Atopic Dermatitis in 2025, with Ama Alexis, MD
© 2025 MJH Life Sciences

All rights reserved.